What question did this study set out to answer?

To determine whether combined treatment using CD4+CD25highCD127- regulatory T cells and anti-CD20 antibody is superior to monotherapy in patients with recent-onset type 1 diabetes.

April 19, 2022Diabetes Obesity and Metabolism

Combined therapy with CD4 + CD25highCD127 − T regulatory cells and anti‐CD20 antibody in recent‐onset type 1 diabetes is superior to monotherapy: Randomized phase I/ II trial

View Full Paper

Ask AI

Bookmark

Authors

MZMaciej ZielińskiPolish Botanical Society MŻMagdalena ŻalińskaGdańsk Medical University DIDorota Iwaszkiewicz‐GrześGdańsk Medical University

Discussion

Member takes

Implication

Randomized trial demonstrates delayed progression with combination cell therapy in recent-onset type 1 diabetes, indicating rituximab and regulatory T cells outperform monotherapy.

Key Points

To determine whether combined treatment using CD4+CD25highCD127- regulatory T cells and anti-CD20 antibody is superior to monotherapy in patients with recent-onset type 1 diabetes.
Conducted a randomized phase I/II clinical trial evaluating combination therapy against single-agent monotherapy in recent-onset type 1 diabetes.
Monitored clinical outcomes and disease progression over a 2-year follow-up period.
Combined therapy with regulatory T cells and rituximab consistently outperformed monotherapy in delaying type 1 diabetes progression over 2 years.
Patients receiving the combination sustained significantly higher C-peptide levels and experienced prolonged maintenance of disease remission compared to monotherapy recipients.

Cite This Study

Zieliński et al. (2022) studied this question.

synapsesocial.com/papers/69d8a20c183921ebcaae3037 https://doi.org/10.1111/dom.14723

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial demonstrates delayed progression with combination cell therapy in recent-onset type 1 diabetes, indicating rituximab and regulatory T cells outperform monotherapy.

Combined therapy with CD4 + CD25highCD127 − T regulatory cells and anti‐CD20 antibody in recent‐onset type 1 diabetes is superior to monotherapy: Randomized phase I/ II trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Combined therapy with CD4 + CD25highCD127 − T regulatory cells and anti‐CD20 antibody in recent‐onset type 1 diabetes is superior to monotherapy: Randomized phase I/ II trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider